These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22970758)

  • 1. Functional screening of pharmacological chaperones via restoration of enzyme activity upon denaturation.
    Shanmuganathan M; Britz-McKibbin P
    Biochemistry; 2012 Oct; 51(39):7651-3. PubMed ID: 22970758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease.
    Sánchez-Ollé G; Duque J; Egido-Gabás M; Casas J; Lluch M; Chabás A; Grinberg D; Vilageliu L
    Blood Cells Mol Dis; 2009; 42(2):159-66. PubMed ID: 19167250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue of misfolded proteins and stabilization by small molecules.
    Stevens RC; Sancho J; Martinez A
    Methods Mol Biol; 2010; 648():313-24. PubMed ID: 20700723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aminocyclitols as pharmacological chaperones for glucocerebrosidase, a defective enzyme in Gaucher disease.
    Egido-Gabás M; Canals D; Casas J; Llebaria A; Delgado A
    ChemMedChem; 2007 Jul; 2(7):992-4. PubMed ID: 17479993
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis of N-substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease.
    Wang GN; Twigg G; Butters TD; Zhang S; Zhang L; Zhang LH; Ye XS
    Org Biomol Chem; 2012 Apr; 10(15):2923-7. PubMed ID: 22286559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
    Tropak MB; Kornhaber GJ; Rigat BA; Maegawa GH; Buttner JD; Blanchard JE; Murphy C; Tuske SJ; Coales SJ; Hamuro Y; Brown ED; Mahuran DJ
    Chembiochem; 2008 Nov; 9(16):2650-62. PubMed ID: 18972510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.
    Patnaik S; Zheng W; Choi JH; Motabar O; Southall N; Westbroek W; Lea WA; Velayati A; Goldin E; Sidransky E; Leister W; Marugan JJ
    J Med Chem; 2012 Jun; 55(12):5734-48. PubMed ID: 22646221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles.
    Sawkar AR; Adamski-Werner SL; Cheng WC; Wong CH; Beutler E; Zimmer KP; Kelly JW
    Chem Biol; 2005 Nov; 12(11):1235-44. PubMed ID: 16298303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.
    Jung O; Patnaik S; Marugan J; Sidransky E; Westbroek W
    Expert Rev Proteomics; 2016 May; 13(5):471-9. PubMed ID: 27098312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
    Trapero A; Llebaria A
    Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New LSD therapies unfolding.
    Kozarich JW
    Chem Biol; 2007 Sep; 14(9):976-7. PubMed ID: 17884629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells.
    Trapero A; Alfonso I; Butters TD; Llebaria A
    J Am Chem Soc; 2011 Apr; 133(14):5474-84. PubMed ID: 21413704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor screening of pharmacological chaperones for lysosomal β-glucocerebrosidase by capillary electrophoresis.
    Shanmuganathan M; Britz-McKibbin P
    Anal Bioanal Chem; 2011 Mar; 399(8):2843-53. PubMed ID: 21286689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.
    Yu L; Ikeda K; Kato A; Adachi I; Godin G; Compain P; Martin O; Asano N
    Bioorg Med Chem; 2006 Dec; 14(23):7736-44. PubMed ID: 16919960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.
    Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG
    Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.
    Orwig SD; Tan YL; Grimster NP; Yu Z; Powers ET; Kelly JW; Lieberman RL
    Biochemistry; 2011 Dec; 50(49):10647-57. PubMed ID: 22047104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of original multivalent iminosugars as pharmacological chaperones for the treatment of Gaucher disease.
    Laigre E; Hazelard D; Casas J; Serra-Vinardell J; Michelakakis H; Mavridou I; Aerts JM; Delgado A; Compain P
    Carbohydr Res; 2016 Jun; 429():98-104. PubMed ID: 27063390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic investigation of iminosugar click clusters as pharmacological chaperones for the treatment of Gaucher disease.
    Joosten A; Decroocq C; de Sousa J; Schneider JP; Etamé E; Bodlenner A; Butters TD; Compain P
    Chembiochem; 2014 Jan; 15(2):309-19. PubMed ID: 24375964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase.
    Goldin E; Zheng W; Motabar O; Southall N; Choi JH; Marugan J; Austin CP; Sidransky E
    PLoS One; 2012; 7(1):e29861. PubMed ID: 22272254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.